Thinking of Investing in ELV? What Our Analysts Know.

By Harris Dyer • Friday, September 01 09:48 • Permanent Link

Elevance Health logged a 1.1% change during today's morning session, and is now trading at a price of $446.87 per share. The S&P 500 index moved 0.0%. ELV's trading volume is 136,752 compared to the stock's average volume of 1,315,034.

Elevance Health trades -21.57% away from its average analyst target price of $569.75 per share. The 20 analysts following the stock have set target prices ranging from $493.0 to $629.0, and on average have given Elevance Health a rating of buy.

Anyone interested in buying ELV should be aware of the facts below:

Elevance Health's current price is 57.0% above its Graham number of $284.59, which implies that at its current valuation it does not offer a margin of safety
Elevance Health has moved -7.0% over the last year, and the S&P 500 logged a change of 17.0%
Based on its trailing earnings per share of 26.87, Elevance Health has a trailing 12 month Price to Earnings (P/E) ratio of 16.6 while the S&P 500 average is 15.97
ELV has a forward P/E ratio of 12.1 based on its forward 12 month price to earnings (EPS) of $37.03 per share
The company has a price to earnings growth (PEG) ratio of 1.06 — a number near or below 1 signifying that Elevance Health is fairly valued compared to its estimated growth potential
Its Price to Book (P/B) ratio is 2.76 compared to its sector average of 4.16
Elevance Health, Inc. operates as a health benefits company.
Based in Indianapolis, the company has 102,300 full time employees and a market cap of $105.3 Billion. Elevance Health currently returns an annual dividend yield of 1.2%.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.